Skip to content

Comparison of the effects of ultrasound-guided puncture sclerotherapy and laparoscopic surgery combined with danazol on ovarian function in the treatment of ovarian endometriosis

A prospective randomized controlled study on the impact of ultrasound-guided puncture sclerotherapy versus laparoscopic stripping combined with dienogest on ovarian function in the treatment of ovarian endometriosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112158
Enrollment
Unknown
Registered
2025-11-11
Start date
2025-11-17
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, EMT

Interventions

Group A: UGIS+DNG Group:After UGIS , take DNG for 12 months
Group B: Surgery +DNG Group:After surgery, take DNG for 12 months

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 18-35 years old; 2. Meet the diagnostic criteria of cystic cyst, and cystic in unilateral ovary, 6cm=1.1ng/ml; 4. No birth plan in the past 12 months.

Exclusion criteria

Exclusion criteria: 1. There are various contraindications to laparoscopic surgery or UGIS puncture. 2. Patients who have contraindications to DNG treatment, or are allergic to DNG, or cannot tolerate the side effects of the drug, or cannot adhere to the drug. 3. If the breast ultrasound grading indicates IVa or above, pathological biopsy is required to exclude malignant lesions. 4. Patients with previous surgical treatment or recurrence of cysts after UGIS treatment. Patients who had undergone ovarian surgery for other ovarian diseases. 5. Preoperative examination for suspected capsular rupture or infection. 6. Use of any medication for the treatment of cystic cysts within 3 months before enrollment, except analgesics and traditional Chinese medicine. 7. Participated in other clinical trials of endometriosis within the past 3 months;

Design outcomes

Primary

MeasureTime frame
AMH(anti-Mullerian hormone,AMH);

Secondary

MeasureTime frame
Therapeutic effect indicators;Safety indicators;

Countries

China

Contacts

Public ContactWeixia Wei

Peking University Shenzhen Hospital

weixwei_2013@126.com+86 755 83923333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026